Skip to main content
. 2021 Mar 17;7:27. doi: 10.1038/s41523-021-00234-8

Fig. 6. Working model for OMO-1 treatment in a 4T1-based intraductal model.

Fig. 6

Key findings upon treatment with OMO-1 are highlighted. More specifically, tumor growth is reduced, neutrophil influx is impaired (decreased MIP-2 levels and Ly6G positivity), and antitumor responses are more pronounced (increased levels of immunostimulatory and tumor suppressive proteins, decreased CD163 positivity). Leaky vessels are normalized to enhance the blood flow to the primary tumor (increased α-SMA, PDGFR-β, and Ang-1 positivity as well as enhanced α-SMA-covered CD31+ vessels), which in turn reduces tumor hypoxia and increases the delivery of chemotherapeutics (increased cisplatin DNA-adducts and cleaved caspase 3 levels).